Expertise in
9
conditions

Anna Spreafico

Toronto, ON, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
9
conditions
Toronto, ON, CA 

Overview

Anna Spreafico practices in Toronto, Canada. Ms. Spreafico is highly rated in 9 conditions, according to our data. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Salivary Gland Tumors, Melanoma, and Human Papillomavirus Infection.

Her clinical research consists of co-authoring 181 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Toronto, ON, Canada
Other Locations
Toronto, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Procedure, Biological
Study Drug: Nivolumab
Study Phase: Phase 1
A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: February 23, 2026
Intervention Type: Drug
Study Drug: SGN-PDL1V
Study Phase: Phase 1
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Biological, Procedure, Drug
Study Drugs: Anetumab ravtansine, Gemcitabine hydrochloride, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 27, 2025
Intervention Type: Biological, Drug
Study Drugs: Cemiplimab, RP1
Study Phase: Phase 2
A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab, Fluorouracil, Cisplatin, Carboplatin
Study Phase: Phase 3
A Phase 1 Study of SRF617 in Patients With Advanced Solid Tumors
A Phase 1 Study of SRF617 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab
Study Phase: Phase 1
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Enrollment Status: Completed
Publish Date: October 12, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Enrollment Status: Completed
Publish Date: February 18, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
A Phase 1 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
Enrollment Status: Completed
Publish Date: October 20, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

181 Total Publications

Practices and Impressions of Head and Neck Cancer Multidisciplinary Tumor Boards Findings From an American Head and Neck Society Survey.
Practices and Impressions of Head and Neck Cancer Multidisciplinary Tumor Boards Findings From an American Head and Neck Society Survey.
Journal: Head & neck
Published: February 08, 2026

Frequently Asked Questions about Anna Spreafico

Is Anna Spreafico a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Anna Spreafico is classified as an Distinguished expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Anna Spreafico participate in research or clinical trials?

Yes. Anna Spreafico has published 181 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Anna Spreafico's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Spreafico's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile